ProfileGDS5678 / 1429239_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 84% 84% 85% 82% 81% 80% 77% 85% 87% 88% 87% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.346578
GSM967853U87-EV human glioblastoma xenograft - Control 26.2079684
GSM967854U87-EV human glioblastoma xenograft - Control 36.2933384
GSM967855U87-EV human glioblastoma xenograft - Control 46.548785
GSM967856U87-EV human glioblastoma xenograft - Control 55.9299782
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6081381
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4856280
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1825977
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3275385
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7412487
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8261888
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7600587
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9805489
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0945289